Mode
Text Size
Log in / Sign up

Skin melanoma

Part of Cancer

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for skin melanoma

32 trials tracked for skin melanoma: 2 in phase 3 or 4.

32Trials tracked
2Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 3 2 Phase 2 21 Phase 1 2 Other / NA 7
  1. Phase 3 SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast Cancer Completed
  2. Phase 3 S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma Completed
  3. Phase 2 Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma Completed
  4. Phase 2 Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma Completed
  5. Phase 2 Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma Completed
  6. Phase 2 Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma Completed
Show 26 more trials
  1. Phase 2 Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma Completed
  2. Phase 2 A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1). Completed
  3. Phase 2 Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma Completed
  4. Phase 2 Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery Completed
  5. Phase 2 Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Completed
  6. Phase 2 Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma Completed
  7. Phase 2 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Completed
  8. Phase 2 Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery Completed
  9. Phase 2 PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma Completed
  10. Phase 2 Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma Completed
  11. Phase 2 Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma Completed
  12. Phase 2 Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma Completed
  13. Phase 2 Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma Completed
  14. Phase 2 Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery Completed
  15. Phase 2 Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma Completed
  16. Phase 2 Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery Completed
  17. Phase 2 Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery Completed
  18. Phase 1 Vaccine Therapy in Treating Patients With Metastatic Melanoma Completed
  19. Phase 1 Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma Completed
  20. N/A Wearable Device Intervention to Improve Sun Behaviors in Melanoma Survivors Completed
  21. N/A Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo Completed
  22. N/A Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers Completed
  23. N/A AI-based Medical Device Validation for Early Melanoma Detection Completed
  24. N/A Skin Health Online for Melanoma: Better Risk Assessment Completed
  25. N/A Patient-led Surveillance Compared to Clinician-led Surveillance in People Treated for Localised Melanoma. Completed
  26. N/A Using MC1R Genotype to Impact Melanoma Risk Behavior Completed

Showing the 32 most-cited and recently-updated of 32 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Cancer

Related studies from across the Cancer family.

Narrowband UVB remains first-line phototherapy for vitiligo, with JAK inhibitors emerging as adjuncts
Rheumatology Sys. Review
Narrowband UVB remains first-line phototherapy for vitiligo, with JAK inhibitors emerging as adjuncts New light therapies and skin grafts offer hope for vitiligo patients
This narrative review synthesizes current evidence on phototherapy for vitiligo, highlighting narrowband UVB as the mainstay. Excimer lasers…
A review of treatments for vitiligo highlights options like narrowband ultraviolet B light, excimer therapy, and cellular grafting that may …
Meta-analysis finds modest melanoma risk increase among infertile women using fertility treatments
Oncology Meta-analysis
Meta-analysis finds modest melanoma risk increase among infertile women using fertility treatments Fertility Drugs Linked to Slight Rise in Melanoma Risk
This systematic review and meta-analysis evaluated melanoma incidence in infertile women exposed to fertility treatments compared to untreat…
A large review finds fertility drugs may raise melanoma risk slightly, but the increase is small and more research is needed.
TIL therapy and engineered viral vector immunotherapies show pooled ORR of 37.8% in advanced melanoma
Oncology Meta-analysis
TIL therapy and engineered viral vector immunotherapies show pooled ORR of 37.8% in advanced melanoma First new analysis in years shows TIL therapy response rates for advanced melanoma
This Bayesian meta-analysis synthesizes data from 13 eligible studies on TIL therapy and engineered viral vector immunotherapies for advance…
A Bayesian meta-analysis of 13 studies finds TIL therapy yields a 49% response rate in advanced melanoma, with moderate certainty for respon…
Systematic Review: Intercellular Mitochondrial Transfer in Melanoma Progression and Resistance
Oncology Sys. Review
Systematic Review: Intercellular Mitochondrial Transfer in Melanoma Progression and Resistance Mitochondrial Transfer Fuels Melanoma Resistance and Spread
This systematic review examines the role of intercellular mitochondrial transfer in melanoma. The authors find that this process contributes…
A systematic review reveals that intercellular mitochondrial transfer helps melanoma resist therapies and spread, but may also suppress tumo…
Meta-analysis finds germline LTS and somatic TERT variants are mutually exclusive in thyroid cancer and melanoma
Genetics & Precision Medicine Meta-analysis
Meta-analysis finds germline LTS and somatic TERT variants are mutually exclusive in thyroid cancer and melanoma Two different cancer drivers do not appear together in these tumors
This meta-analysis of retrospective observational cohorts examined germline long-telomere syndrome variants and somatic TERT promoter altera…
A large review of nearly 2,000 adults with thyroid cancer or melanoma found that two specific genetic changes never occur in the same tumor.
Systematic review and meta-analysis of AI for melanoma risk assessment in pigmented skin lesions
Dermatology Meta-analysis
Systematic review and meta-analysis of AI for melanoma risk assessment in pigmented skin lesions AI plus doctors finds every skin cancer case in real-world settings
This systematic review and meta-analysis synthesized evidence from 17 diagnostic arms on AI, dermoscopy, and AI-assisted clinicians for mali…
When doctors used AI alongside standard skin checks, they caught every cancer case without missing any, showing a powerful new way to help p…
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
Oncology FDA Approval
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…
Systematic review and meta-analysis on alopecia areata and skin cancer risk
Oncology Meta-analysis
Systematic review and meta-analysis on alopecia areata and skin cancer risk Alopecia areata patients may have lower risk of certain skin cancers based on new review data
This systematic review and meta-analysis synthesized eight studies on skin cancer risk in patients with alopecia areata. The analysis found …
This review found that people with hair loss might have a lower chance of getting melanoma. Other skin cancers showed a similar trend but th…
Early time-of-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors
Oncology Meta-analysis
Early time-of-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors Cancer Patients Live Longer When Immunotherapy Starts Early in Day
This systematic review and meta-analysis evaluated 6129 patients with advanced solid tumors receiving immune checkpoint inhibitors. Earlier …
• Morning immunotherapy shots link to longer survival for advanced cancers • Helps patients fighting lung stomach kidney and other tough can…
Meta-analysis of pucotenlimab shows improved outcomes across multiple solid tumors
Oncology Meta-analysis
Meta-analysis of pucotenlimab shows improved outcomes across multiple solid tumors New analysis shows pucotenlimab improves outcomes for several solid tumor types
This meta-analysis evaluated pucotenlimab (HX008) in patients with gastric, gastroesophageal junction, triple-negative breast cancer, melano…
A new analysis of pucotenlimab shows significantly improved outcomes versus control for patients with gastric cancer, triple-negative breast…
Narrative review discusses MicroRNAs in melanoma without reported outcomes or safety data
Rheumatology Sys. Review
Narrative review discusses MicroRNAs in melanoma without reported outcomes or safety data A review explores how MicroRNAs might relate to Melanoma
This narrative review examines the role of MicroRNAs in melanoma.
This narrative review discusses MicroRNAs in the context of Melanoma, offering a broad overview of current scientific understanding.
Methodological study evaluates synthetic image framework for melanoma classification accuracy in preprint report
Dermatology
Methodological study evaluates synthetic image framework for melanoma classification accuracy in preprint report New image method boosts tumor detection accuracy in melanoma datasets
This preprint describes a methodological study evaluating a hybrid framework using synthetic medical images to train convolutional neural ne…
A new way to train computer models improved how well they spot melanoma cells. This approach uses synthetic images to help computers learn b…